> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# 6 Observations in Hetero Labs ’483
- URL: https://www.fdaweb.com/6-observations-in-hetero-labs-483/
- Published: 2025-10-15T12:00:00.000Z
- Updated: 2026-09-14T15:24:11.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5160047

FDA has released the form FDA-483 issued following a 9/19-9/26 inspection at the Hetero Labs Unit 9 active pharmaceutical ingredient (API) manufacturing facility in Narasapuram Village, India. The six observations in the 12-page report were:

- failure to maintain in writing and fully follow the responsibilities and procedures applicable to the quality control unit;
- release of finished APIs and intermediates intended for the U.S. market to an offsite API warehouse without documentation;
- raw materials and quantities documented in batch production records do not support the yields observed for the APIs produced at the firm;
- failure of the quality unit to adequately control documents;
- failure to reconcile the quantities of identification labels issued, used, and returned; and
- failure to document and investigate out-of-specification results obtained by an unregistered facility testing the firm’s APIs and intermediates.